Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer
- 193 Downloads
BCL2 (B-cell leukemia/lymphoma 2) gene functions as antiapoptotic regulatory element and known to be associated with tumorigenesis. The SNP-938 (C>A) (rs2279115), located in the inhibitory P2 promoter of the BCL2 gene, influences differential binding affinities of transcriptional factors thereby affecting BCL2 expression. The present study is an attempt to evaluate the association between BCL2(-938C>A) polymorphism and clinical characteristics of breast cancer patients as well as to analyze BCL2 expression and Ki67 proliferation index with respect to the genotypes. One hundred ten primary breast cancer tumor tissues were genotyped for -938 C>A polymorphism through PCR-RFLP method as well as evaluated for BCL2 expression and ki67 proliferation index by immunohistochemistry. Evaluation of apoptosis level was performed by flowcytometry. The results revealed that AA genotype was associated with an increased risk (AA Vs AC + CC) by 2.86-fold (p = 0.07) for breast cancer development which reflected in elevated A allele frequency also. AA genotype was found to be predominant among BCL2 positive tumors as compared to BCL2 negative tumors. Further, AA genotype was found to be associated with advanced stage tumors, node positive status, and high Ki67 proliferation index compared to CA and CC genotypes indicating that elevated expression of BCL2 gene in the presence of A allele might be associated with decreased apoptosis and enhanced proliferation rate. AA genotype of BCL2-938C>A polymorphism might influence BCL2 gene expression there by associated with elevated risk for breast cancer progression. Probably, failure of apoptosis due to enhanced expression and antiapoptotic protein BCL2 might promote malignant growth.
KeywordsBCL2 Apoptosis Immunohistochemistry Ki67 proliferation index Flow cytometry Breast cancer
We would like to thank MNJ institute of oncology and regional cancer centre, Hyderabad, India for providing samples from breast cancer patients.
Compliance with ethical standards
Conflicts of interest
This study was funded by University Grants Commission-Centre for Advanced Studies (UGC-CAS-II), New Delhi and DBT-OU-ISLARE. Phanni bhushann Meka is thankful to UGC-CAS-II for providing fellowship.
- 8.Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Meka P et al. Influence of BCL2 -938C > A and BAX-248G > A promoter polymorphisms in the development of AML: case-control study from South India. Tumor Biol. 2015;36(10): 7967–76.Google Scholar
- 11.Nuckel H, Frey UH et al. Association of a novel regulatory polymorphism (_938C_A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109(1):290–7.Google Scholar
- 14.Pikor LA, Enfield KS, Cameron H, Lam WL. DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp. 2011;49:2763.Google Scholar
- 16.Kim OH, Jo HY, Lee J, Yoon SK. The C1772T genetic polymorphism in human HIF-1α gene associates with expression of HIF-1α protein in breast cancer. Oncol. Rep. 2008;20(5):1181–7.Google Scholar